Search Result

Isoforms Recommended:	PDE6

Results for "

PDE6

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (2) Casein Kinase (2) Drug Metabolite (1) Endogenous Metabolite (16) Isotope-Labeled Compounds (4) Molecular Glues (3) mTOR (1) NAMPT (1) NO Synthase (5) Phosphodiesterase (PDE) (31) PI3K (1) Ras (2) Reference Standards (6) Small Interfering RNA (siRNA) (12)
By Research Areas:	Cancer (13) Cardiovascular Disease (8) Endocrinology (15) Inflammation/Immunology (12) Metabolic Disease (10) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (3) Mouse Pre-designed siRNA Sets (3) Human Pre-designed siRNA Sets (6) siRNAs (12)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS10230

PDE6A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE6A Human Pre-designed siRNA Set A contains three designed siRNAs for PDE6A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE6A Human Pre-designed siRNA Set A PDE6A Human Pre-designed siRNA Set A

HY-RS10232

Pde6a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde6a Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde6a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde6a Rat Pre-designed siRNA Set A Pde6a Rat Pre-designed siRNA Set A

HY-RS10231

Pde6a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde6a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde6a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde6a Mouse Pre-designed siRNA Set A Pde6a Mouse Pre-designed siRNA Set A

HY-RS10237

PDE6H Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE6H Human Pre-designed siRNA Set A contains three designed siRNAs for PDE6H gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE6H Human Pre-designed siRNA Set A PDE6H Human Pre-designed siRNA Set A

HY-RS21685

Pde6c Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde6c Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde6c gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde6c Mouse Pre-designed siRNA Set A Pde6c Mouse Pre-designed siRNA Set A

HY-RS22712

Pde6d Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde6d Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pde6d gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde6d Mouse Pre-designed siRNA Set A Pde6d Mouse Pre-designed siRNA Set A

HY-RS10234

PDE6C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE6C Human Pre-designed siRNA Set A contains three designed siRNAs for PDE6C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE6C Human Pre-designed siRNA Set A PDE6C Human Pre-designed siRNA Set A

HY-RS29226

Pde6d Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde6d Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde6d gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde6d Rat Pre-designed siRNA Set A Pde6d Rat Pre-designed siRNA Set A

HY-RS10233

PDE6B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE6B Human Pre-designed siRNA Set A contains three designed siRNAs for PDE6B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE6B Human Pre-designed siRNA Set A PDE6B Human Pre-designed siRNA Set A

HY-RS10236

PDE6G Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE6G Human Pre-designed siRNA Set A contains three designed siRNAs for PDE6G gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE6G Human Pre-designed siRNA Set A PDE6G Human Pre-designed siRNA Set A

HY-RS10235

PDE6D Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDE6D Human Pre-designed siRNA Set A contains three designed siRNAs for PDE6D gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDE6D Human Pre-designed siRNA Set A PDE6D Human Pre-designed siRNA Set A

HY-RS28203

Pde6c Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pde6c Rat Pre-designed siRNA Set A contains three designed siRNAs for Pde6c gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pde6c Rat Pre-designed siRNA Set A Pde6c Rat Pre-designed siRNA Set A

HY-172919

PDEδ/NAMPT IN-1	Phosphodiesterase (PDE) NAMPT Apoptosis	Cancer
PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) (K_D=0.410 nM) and nicotinamide phosphoribosyl transferase (NAMPT) (IC₅₀=2.21 nM). PDEδ/NAMPT IN-1 blocks KRAS-related signal transduction and interferes with the synthesis of nicotinamide adenine dinucleotide (NAD ⁺), inducing apoptosis in KRAS mutant pancreatic cancer cells. PDEδ/NAMPT IN-1 is promising for research of KRAS mutant pancreatic cancer .

HY-128060

PDE5-IN-42	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-42 (Compound 42) is a potent and orally active *PDE5* inhibitor with an IC₅₀ of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11 .

HY-19420

UK 357903	Phosphodiesterase (PDE)	Others
UK 357903 is a selective inhibitor for phosphodiesterase 5 (PDE5), with IC₅₀s of 1.7 and 714 nM, for *PDE5* and *PDE6*. UK 357903 exhibits vasodilatory effects on the mesenteric and hindlimb vascular beds, and is potential for ameliorating erectile dysfunction .

HY-149661

PDE5-IN-11	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-11 is a potent inhibitor of *PDE5* with an IC₅₀ of 40 nM. PDE5-IN-11 also inhibits *PDE4* and *PDE6* with IC₅₀s of 1.78 and 0.09 μM, respectively .

HY-105349

T-0156	Phosphodiesterase (PDE)	Neurological Disease
T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 enhances the nitric oxide (NO)/cGMP pathway .

HY-164685

T-0156 free base	Phosphodiesterase (PDE)	Neurological Disease
T-0156 free base is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 free base specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC₅₀=0.23 nM). T-0156 free base inhibits PDE6 (IC₅₀=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC₅₀>10 μM). T-0156 free base enhances the nitric oxide (NO)/cGMP pathway .

HY-B0442C

Vardenafil dihydrochloride	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- ^[6].

HY-B0442

Vardenafil 3 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 3 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442S

Vardenafil-d5	Isotope-Labeled Compounds Phosphodiesterase (PDE) Endogenous Metabolite	Endocrinology
Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-B0442B

Vardenafil hydrochloride trihydrate 3 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252

Avanafil 1 Publications Verification TA1790	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Drug Metabolite Reference Standards Endogenous Metabolite	Metabolic Disease
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-B0442AR

Vardenafil hydrochloride (Standard)	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-B0442R

Vardenafil (Standard)	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Reference Standards Others	Inflammation/Immunology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite	Cardiovascular Disease Endocrinology
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-18252S3

Avanafil-13C5 TA1790-¹³C₅	Isotope-Labeled Compounds Endogenous Metabolite Phosphodiesterase (PDE) NO Synthase	Cardiovascular Disease Endocrinology
Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2	Endogenous Metabolite NO Synthase Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Endocrinology
Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-122641

Deltasonamide 1	Phosphodiesterase (PDE)	Cancer
Deltasonamide 1 is a *PDE6δ-KRas* inhibitor. Deltasonamide 1 can inhibit PDE6δ-KRas with a K_D of 203 pM. Deltasonamide 1 can be used for the research of tumors .

HY-122641D

Deltasonamide 1 TFA	Phosphodiesterase (PDE)	Cancer
Deltasonamide 1 TFA is a *PDE6δ-KRas* inhibitor. Deltasonamide 1 can inhibit PDE6δ-KRas with a K_D of 203 pM. Deltasonamide 1 can be used for the research of tumors .

HY-163636

Deltaflexin3 A-442b	Phosphodiesterase (PDE) Ras	Cancer
Deltaflexin3 is a potent *PDE6D* inhibitor. Deltaflexin3 reduces the signaling of Ras and selectively decreases the KRAS mutant and PDE6D-dependent cancer cells growth .

HY-174379

KRAS IN-44	Phosphodiesterase (PDE) Ras PI3K Akt mTOR Apoptosis	Cancer
KRAS IN-44 (Compound S2C2M2) is a *PDE6D* degrader. KRAS IN-44 inhibits PDE6D-dependent KRAS trafficking and KRAS downstream signaling pathways. KRAS IN-44 down-regulates EGF-induced the phosphorylation of PI3K, AKT, and mTOR. KRAS IN-44 increases Apoptosis. KRAS IN-44 has antitumor activity against hepatoblastoma .

HY-145321

TMX-4100	Phosphodiesterase (PDE) Molecular Glues	Cancer
TMX-4100 is a selective phosphodiesterase 6D (PDE6D) degrader. TMX-4100 shows a high degradation preference for PDE6D with the DC₅₀ values less than 200 nM in MOLT4, Jurkat, and MM.1S cells. TMX-4100 can be used for the research of multiple myeloma .

HY-145320

TMX-4113	Molecular Glues Phosphodiesterase (PDE) Casein Kinase	Cancer
TMX-4113 is a degrader of phosphodiesterase 6D (PDE6D) and casein kinase 1α (CK1α). TMX-4113 can be used for the research of cancer .

HY-130262

PDE1-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE1-IN-3, compound 4 (WO2019156861), is a selective human phosphodiesterase 1 (PDE1) inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC₅₀ values of 23.99 μM and 10 μM, respectively .

HY-145319

FPFT-2216	Phosphodiesterase (PDE) Casein Kinase Molecular Glues	Inflammation/Immunology Cancer
FPFT-2216, a “molecular glue” compound, degrades phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1), Aiolos (IKZF3), and casein kinase 1α (CK1α). FPFT-2216 can be used for the research of cancer and inflammatory disease .

HY-112704

PDE5-IN-2	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-2 is a potent, highly selective, and orally active *PDE5* inhibitor, with an IC₅₀ of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC₅₀s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity .

HY-112831

Osoresnontrine 1 Publications Verification BI-409306	Phosphodiesterase (PDE)	Neurological Disease
Osoresnontrine (BI-409306) is a potent and selective *PDE9A* inhibitor, with an IC₅₀ of 52 nM, and shows weak activity against other PDEs, such as PDE1A (IC₅₀, 1.4 µM), PDE1C (IC₅₀, 1.0 µM), PDE2A, PDE3A, PDE4B, PDE5A, PDE6AB, PDE7A, and PDE10A (IC₅₀ all > 10 μM); Osoresnontrine can be used in the research of memory enhancement in CNS disorders.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0442

Vardenafil 3 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 3 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442B

Vardenafil hydrochloride trihydrate 3 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252

Avanafil 1 Publications Verification TA1790	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442C

Vardenafil dihydrochloride	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- ^[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Structural Classification Monophenols Source classification Phenols Endogenous metabolite	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252A

Avanafil dibenzenesulfonate TA1790 dibenzenesulfonate	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology	Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis .

HY-113972R

Methyl mycophenolate (Standard)	Structural Classification Monophenols Microorganisms Marine natural products Phenols Marine microorganism	Reference Standards Others
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252R

Avanafil (Standard) TA1790 (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Phosphodiesterase (PDE) NO Synthase Endogenous Metabolite
Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - ^[6].

Cat. No.	Compare	Product Name	Species	Source

HY-P702973

	PDE6D Protein, Human (sf9, GST) PDED	Human	Sf9 insect cells
	PDE6D Protein, Human (sf9, GST) is the recombinant human-derived PDE6D, expressed by Sf9 insect cells , with GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-18252S3

Avanafil-13C5

Avanafil- ¹³C₅ (TA1790- ¹³C₅) is ¹³C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

HY-18252S1

Avanafil-13C5,15N,d2

Avanafil- ¹³C₅, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC₅₀ values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks